Hematologist when colleagues prescribe oral iron 3x daily for iron deficiency anemia🤣

#BladderCancer: Role of ctDNA in treatment de-escalation. Presentation by Dr. John Sfakianos Mount Sinai Health System. #EAU25 written coverage by Julian Chavarriaga University of Toronto > bit.ly/4hx9AVR European Association of Urology (EAU)

🧬 cfDNA fragmentomics is redefining cancer detection. Beyond mutations & methylation, genome-wide fragmentation patterns offer new biomarkers. 🔹 Reflects genomic & epigenomic states 🔹 Enhances early detection via AI-driven analysis 📖 Nature Reviews Cancer DOI:

1/2 REMEMBER THE DOAC vs NOAC DEBATE? The 1st oral anticoagulant, warfarin, was approved by the FDA in 1954. In 2010, the FDA approved its first DOAC, dabigatran, followed by rivaroxaban (2011), apixaban (2012), in edoxaban (2015).

Durvalumab now U.S. FDA approved in resectable MIBC based off #NIAGARA: Ph III, Gem/Cis +/- Durvalumab —> ✂️ —> post-op Durva - New SoC - 2 yr OS: 82.2% vs. 75.2% (HR: 0.75) - 2yr EFS: 67.8% vs. 59.8% (HR: 0.68) - Do we need adj Durva if pCR? #OncTwitter #MedTwitter #gusm

BREAKING from NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.

SUBSEGMENTAL PULMONARY EMBOLISM ... to anticoagulate or not to anticoagulate??

Cancer of unknown primary site encompasses a heterogeneous group of metastatic cancers with an unidentified primary site of origin. Putative site-specific therapy and empirical chemotherapy are acceptable treatment options. Read the Clinical Practice article “Cancer of Unknown

1/2 Thanks to Prashant Chaulagain for this infographic that he developed during his MedEd elective. IgG4-Related Disease (IgG4-RD) A great mimicker of malignancy & infection. Think IgG4-RD when you see:

🚨 Wow! #ASCO25 ASCO was absolutely massive! 10 NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

Attending my first ASCO Meeting was more than just a conference—it was an experience, a pulse. Grateful for all the mentors, peers, and friends I met along the way. Until next time, ASCO—thank you for the inspiration, the knowledge, and the memories. Thank you, Chicago! #ASCO25

Truly humbled and honored to be named ‘Resident of the Year.’ and awarded with “Albert J. Himelfarb Award in Professionalism and Humanism” Words cannot express my gratitude for the unwavering support of my incredible colleagues and the guidance of my inspiring mentors.

Excited to share that two of our abstracts have been accepted for poster presentation at the #ASCOQLTY 2025 Symposium! Looking forward to presenting our research on innovation in medical education and empathy among residents. IMG Oncologists OncLive.com ASCO #MedEd #empathy

Prashant Chaulagain IMG Oncologists OncLive.com ASCO We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/blog/prashant-…

At the end,it always comes down to just two choices; Get busy living, or get busy dying... #stephenking